Table 4 Reclassification tables comparing clinical categories of chemotherapy benefit from standalone PREDICT and PREDICT with (a) Oncotype DX, (b) EndoPredict, (c) MammaPrint and (d) Prosigna in ER-positive patients
From: Evaluation and comparison of different breast cancer prognosis scores based on gene expression data
PREDICT + Oncotype DX | |||
|---|---|---|---|
Low | Intermediate | High | |
(a) | |||
PREDICT | |||
Low | 893 | 19 | 0 |
Intermediate | 27 | 434 | 7 |
High | 0 | 21 | 477 |
PREDICT + EndoPredict | |||
|---|---|---|---|
Low | Intermediate | High | |
(b) | |||
PREDICT | |||
Low | 890 | 22 | 0 |
Intermediate | 46 | 407 | 15 |
High | 0 | 49 | 449 |
PREDICT + MammaPrint | |||
|---|---|---|---|
Low | Intermediate | High | |
(c) | |||
PREDICT | |||
Low | 873 | 39 | 0 |
Intermediate | 54 | 380 | 34 |
High | 0 | 27 | 471 |
PREDICT + Prosigna | |||
|---|---|---|---|
Low | Intermediate | High | |
(d) | |||
PREDICT | |||
Low | 877 | 34 | 1 |
Intermediate | 60 | 388 | 20 |
High | 0 | 68 | 430 |